MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
42.98
-0.97
-2.21%
After Hours: 42.50 -0.48 -1.12% 19:48 02/10 EST
OPEN
43.97
PREV CLOSE
43.95
HIGH
44.28
LOW
42.93
VOLUME
3.25M
TURNOVER
--
52 WEEK HIGH
49.62
52 WEEK LOW
32.38
MARKET CAP
11.52B
P/E (TTM)
18.09
1D
5D
1M
3M
1Y
5Y
1D
Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch
Seeking Alpha · 12h ago
Exelixis: Solid Q4 Execution and Advancing Pipeline Underpin Buy Rating and 2026 Earnings Power
TipRanks · 14h ago
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
NASDAQ · 14h ago
Exelixis (EXEL) Q4 2025 Earnings Call Transcript
The Motley Fool · 15h ago
Exelixis reports Q4 EPS 94c, consensus 81c
TipRanks · 17h ago
Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.6B
TipRanks · 17h ago
Oncology company Exelixis Q4 revenue slightly misses estimates
Reuters · 17h ago
Exelixis Non-GAAP EPS of $0.97 beats by $0.16, revenue of $598.66M misses by $2.44M
Seeking Alpha · 17h ago
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.